The Technical AnalystExchange: HKSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Pak Fah Yeow Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.44% HKD2.12
America/New_York / 3 mai 2024 @ 03:55
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 660.68 mill |
| EPS: | 0.340 |
| P/E: | 6.24 |
| Earnings Date: | Mar 25, 2024 |
| SharesOutstanding: | 311.64 mill |
| Avg Daily Volume: | 0.0621 mill |
| RATING 2024-05-03 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.18x |
| Company: PE 6.24 | sector: PE 34.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.48x |
| Company: PE 6.24 | industry: PE 13.09 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
HKD 2.07 - 2.17 ( +/- 2.50%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | HKD2.12 (1.44% ) |
| Volume | 0.0625 mill |
| Avg. Vol. | 0.0621 mill |
| % of Avg. Vol | 100.68 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 0239.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
0239.HK
Pak Fah Yeow International Limited, together with its subsidiaries, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the United Kingdom, and internationally. It operates through three segments: Healthcare, Property Investments, and Treasury Investments. The company offers white flower embrocation medicated oils, strain relief products, and ointments under, as well as Fúzai 239, a floral-scented white flower embrocation. In addition, it invests in commercial, industrial, residential, and car park properties; and provides advertising agency services. The company was founded in 1927 and is headquartered in Wan Chai, Hong Kong.